Cargando…
Inhibitor of Apoptosis Proteins (IAPs) as therapeutic targets in Multiple Myeloma (MM)
The inhibitor of apoptosis (IAP) proteins plays a critical role in the control of apoptotic machinery, and has been explored as a therapeutic target. Here, we have examined the functional importance of IAPs in multiple myeloma (MM) by using a Smac-mimetic LCL161. We observed that LCL161 was able to...
Autores principales: | Ramakrishnan, Vijay, Painuly, Utkarsh, Kimlinger, Teresa, Haug, Jessica, Rajkumar, S. Vincent, Kumar, Shaji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090267/ https://www.ncbi.nlm.nih.gov/pubmed/24402161 http://dx.doi.org/10.1038/leu.2014.2 |
Ejemplares similares
-
Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2018) -
Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway
por: Ramakrishnan, Vijay, et al.
Publicado: (2012) -
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
por: Ramakrishnan, Vijay, et al.
Publicado: (2016) -
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
por: Ramakrishnan, Vijay G., et al.
Publicado: (2019) -
Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013)